HOME > BUSINESS
BUSINESS
- Susmed Wins Partial Change Approval for Insomnia App, Seeks Coverage
September 8, 2025
- Ferring Files for Japan Approval of Bladder Cancer Gene Therapy
September 8, 2025
- Kaken’s Onychomycosis Drug Grabs German Approval
September 8, 2025
- Japan Ethical Drug Sales Inch Up 0.7% in July: Crecon
September 8, 2025
- Nichi-Iko Shows Signs of Recovery but Restructuring Still Underway: CEO
September 5, 2025
- And Pharma Chief Pledges Growth Strategy as New Generics Holding Firm Takes Shape
September 5, 2025
- New Study of Vasomune-Partnered AV-001 Cleared in Canada: AnGes
September 5, 2025
- Keytruda Top-Selling Drug in Japan for 23 Months Running: Encise
September 5, 2025
- Eisai Begins FDA Rolling Submission for Leqembi SC for Starting Dose
September 4, 2025
- FDA Accepts Xocova NDA for COVID Post-Exposure Prophylaxis
September 4, 2025
- Bayer Pushes Cross-Border Open Innovation with New Co.Lab Connect Program
September 4, 2025
- ASKA Repeats Request to Dalton after Dismissive Email on Stake Plan
September 3, 2025
- Kaken’s Hyperhidrosis Drug Ecclock Gets Approval in South Korea
September 3, 2025
- Mitsubishi Tanabe Releases OD Tablet Form of Canalia in Japan
September 3, 2025
- Fuji, Nitto Strike Sales Deal for Eylea Biosimilar, Eye November Listing
September 2, 2025
- Shionogi Completes Full Takeover of Torii under JT Deal
September 2, 2025
- Teva Takeda Renamed as T’s Pharma
September 2, 2025
- FDA Clears Leqembi Autoinjector; Launch Set for Oct. 6
September 2, 2025
- Santen’s Glaucoma Drug Tapcom Launched in China
September 2, 2025
- Takeda Wins Japan Approval for Takhzyro Pen Formulation
September 2, 2025
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
